Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now
Buenos Aires - Delayed Quote ARS

Biogen Inc. (BIIB.BA)

Compare
13,125.00
0.00
(0.00%)
At close: February 28 at 4:59:07 PM GMT-3
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
9,675,900
9,675,900
9,835,600
10,173,400
10,981,700
Cost of Revenue
2,310,400
2,310,400
2,533,400
2,278,300
2,109,700
Gross Profit
7,365,500
7,365,500
7,302,200
7,895,100
8,872,000
Operating Expense
5,146,600
5,146,600
5,471,100
4,993,200
6,064,000
Operating Income
2,218,900
2,218,900
1,831,100
2,901,900
2,808,000
Net Non Operating Interest Income Expense
-182,700
-182,700
29,600
-157,300
-242,600
Other Income Expense
-130,200
-130,200
-563,900
847,200
-820,200
Pretax Income
1,906,000
1,906,000
1,296,800
3,591,800
1,745,200
Tax Provision
273,800
273,800
135,300
632,800
52,500
Earnings from Equity Interest Net of Tax
--
--
--
2,600
34,900
Net Income Common Stockholders
1,632,200
1,632,200
1,161,100
3,046,900
1,556,100
Diluted NI Available to Com Stockholders
1,632,200
1,632,200
1,161,100
3,046,900
1,556,100
Basic EPS
11.10
11.21
8.02
20.96
10.44
Diluted EPS
11.06
11.18
7.97
20.87
10.40
Basic Average Shares
145,300
145,600
144,700
145,300
149,100
Diluted Average Shares
145,975
145,900
145,600
146,000
149,600
Total Operating Income as Reported
--
--
--
--
2,840,700
Total Expenses
7,457,000
7,457,000
8,004,500
7,271,500
8,173,700
Net Income from Continuing & Discontinued Operation
1,632,200
1,632,200
1,161,100
3,046,900
1,556,100
Normalized Income
1,794,155.20
1,794,155.20
1,663,218.40
2,340,484.80
2,346,262
Interest Income
67,600
67,600
276,500
89,300
11,000
Interest Expense
250,300
250,300
246,900
246,600
253,600
Net Interest Income
-182,700
-182,700
29,600
-157,300
-242,600
EBIT
2,156,300
2,156,300
1,543,700
3,838,400
1,998,800
EBITDA
2,829,500
2,829,500
2,038,500
4,356,800
2,880,100
Reconciled Cost of Revenue
2,083,900
2,083,900
2,279,200
2,125,800
2,503,300
Reconciled Depreciation
673,200
673,200
494,800
518,400
487,700
Net Income from Continuing Operation Net Minority Interest
1,632,200
1,632,200
1,161,100
3,046,900
1,556,100
Total Unusual Items Excluding Goodwill
-189,200
-189,200
-560,400
857,300
-814,600
Total Unusual Items
-189,200
-189,200
-560,400
857,300
-814,600
Normalized EBITDA
3,018,700
3,018,700
2,598,900
3,499,500
3,694,700
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-27,244.80
-27,244.80
-58,281.60
150,884.80
-24,438
12/31/2021 - 3/17/2020

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

AMGN.MX Amgen Inc.
6,032.00
0.00%
 
AMGN.BA Amgen Inc.
12,500.00
+0.81%
 
PFEB.F Pfizer Inc.
7.75
-1.27%
 
MRK.BA Merck & Co., Inc.
22,375.00
+1.94%
 
PFE.BA Pfizer Inc.
7,990.00
-0.12%
 
GSK.L GSK plc
1,466.50
+0.38%
 
GSK GSK plc
37.59
+0.78%
 
AMGN Amgen Inc.
308.06
+0.73%
 
GILD Gilead Sciences, Inc.
114.31
+2.07%
 
BMY Bristol-Myers Squibb Company
59.62
+1.39%